查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1830305

HIV疫苗市场（依疫苗类型、技术、给药途径、最终用户和分销管道）－2025-2032年全球预测

HIV Vaccines Market by Vaccine Type, Technology, Route Of Administration, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，HIV 疫苗市场规模将成长至 25.5237 亿美元，复合年增长率为 13.29%。

主要市场统计数据
基准年2024年 9.4005亿美元
预计2025年 10.6416亿美元
预测年份：2032年 2,552,370,000美元
复合年增长率（%） 13.29%

简明指南：科学、监管和营运力量如何融合，共同影响爱滋病毒疫苗的开发和计画重点

HIV疫苗研发在免疫学、病毒学和全球公共卫生策略的交叉领域中发挥关键作用。抗原设计、递送平台和免疫调节技术的最新科学进展正在重新定义技术可实现性，同时法律规范和临床试验设计也不断适应新的模式。包括公共卫生机构、学术联盟和私人开发商在内的相关人员正在应对复杂的科学权衡、不断变化的社会期望以及对永续生产和分销方法的需求所塑造的局面。

本执行摘要旨在总结最重要的进展，并明确其对决策者的策略意义。它揭示了不断变化的平台技术偏好、监管调整和地缘政治动态如何影响各个开发组合的优先事项。摘要也阐明了给药途径选择、最终用户需求和分销管道如何与技术选择和临床策略相互交织。透过梳理这些因素，引言为切实可行的见解奠定了基础，这些见解有助于研究、临床和商业相关人员确定专案优先顺序、建立伙伴关係关係并产业计画。

平台多样化、给药途径优化、监管协调和协作模式如何改变爱滋病毒疫苗策略

HIV疫苗领域正在经历一系列变革，这些变革时期正在重新定义研究策略、投资重点和合作架构。首先，平台多样化正在推动平行发展路径。虽然重组蛋白和类病毒颗粒构建体等传统方法对于特定免疫谱仍然重要，但基于核苷酸的平台（例如常规mRNA和自扩增mRNA）因其快速的设计週期和灵活的抗原呈现方式，正重新引起人们的关注。同时，病毒载体和胜肽策略也在不断改进，以提高安全性、反应持久性和靶向细胞免疫。

其次，免疫原设计与给药途径选择的整合正成为临床策略的关键决定因素。虽然肌肉注射仍然是许多候选药物的预设给药方式，但鼻内和皮下途径由于其在黏膜免疫和节省剂量方面的优势而正在被重新考虑。第三，监管机构越来越重视一致的终点、自适应试验设计和真实世界数据的整合。最后，共同研究模式也在改变。多利益相关者相关利益者、官民合作关係和新型授权安排正在成为平衡科学风险、资本强度和国际准入目标的标准机制。总的来说，这些转变扩展了专案领导者可行策略的范围，同时也提升了综合技术、监管和商业规划的重要性。

评估 2025 年关税变化如何重塑整个 HIV 疫苗价值链的采购、製造足迹和联合生产策略

2025年左右宣布的关税政策变化，为疫苗供应链、筹资策略和跨境合作带来了新的考量。某些原料、零件和成品的关税上调，可能会影响生产基地的成本竞争力，并影响疫苗成品和关键中间体的产地决策。这些动态提升了供应链透明度和策略采购的重要性，以减少对关键试剂和耗材单一国家供应商的依赖。

除了直接的成本影响外，关税波动还会导致营运摩擦，延长前置作业时间并使库存计划变得复杂。製造商和经销商正在采取多种应对措施，包括建立多元化供应商网路、提昇在岸或近岸製造能力，以及重新协商长期供应协议以纳入关税意外事件。采购团队还必须调整合约措辞，以应对海关合规性、关税减免条款以及产品跨越多个司法管辖区时可能出现的监管差异。

重要的是，关税会影响合作。研究合作和製造业伙伴关係可能会强调本地生产和技术转让，以避免跨国成本并与国家产业政策保持一致。政策制定者和业界都在评估关税制度如何影响公平准入目标，并越来越关注在维持可负担性的同时支持具有韧性的製造业生态系统的合作机制。

综合细分洞察，将疫苗类型、平台技术、给药途径、最终用户动态和分销选项与策略决策联繫起来

细緻地审视细分市场，可以发现产品策略、技术选择、给药途径、用户需求和通路如何相互作用，从而决定开发和商业化的重点。在评估疫苗类型时，预防方法包括传统的灭活病毒、减毒活疫苗、重组蛋白疫苗和类病毒颗粒候选物，每种疫苗都有不同的免疫抗原性特征和生产影响。技术选择涵盖DNA、mRNA、胜肽和病毒载体平台，其中mRNA类别本身又分为传统的mRNA构建体和旨在增强抗原表达和给药效率的自扩增mRNA。

给药途径（肌肉注射、鼻腔注射、皮下注射）既影响免疫接种的原理，也影响部署的营运物流，进而影响低温运输需求和管理培训。最终用户细分揭示了诊所、医院、製药公司和研究机构的不同需求。在诊所内部，医院附属诊所和独立诊所之间的差异会影响采购管道和病患流程设计，而私人医院和公立医院的采购框架和预算週期也有所不同。分销管道的选择——直销、线上销售或零售药局——进一步决定了医疗服务提供者的参与模式和病患获取途径。这些细分维度共同构成了开发人员和专案经理的多维决策矩阵，必须在科学、监管和商业性时间表上进行协调。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和战略要务将决定监管协调和部署准备情况

区域动态对于爱滋病毒疫苗研发、监管策略和部署的策略规划至关重要。美洲的监管环境拥有先进的临床试验基础设施和多元化的支付方组合，鼓励循序渐进的临床路径，并与学术中心和私人製造商建立合作伙伴关係。由于各国的智慧财产权框架和采购机制各不相同，跨境策略通常优先考虑与国家监管机构和支付方进行早期接触，以协调证据包和报销预期。

欧洲、中东和非洲地区情况复杂，监管协调工作与生产能力和医疗保健可近性的巨大差异并存。该地区亟需制定灵活的发展计划，以适应不同的临床试验人群，并整合技术转移要素，从而建立永续的本地能力。与区域公共卫生机构和多边采购组织的合作通常对于确保广泛的可及性和协调部署重点至关重要。

亚太地区展现出一系列能力，从高产量的生产中心到快速现代化的监管体系和广泛的临床试验网络。开发商通常会寻求区域生产协议或战略许可，以利用生产规模并满足当地监管要求。在所有地区，当地相关人员关係、监管透明度和生产韧性仍然是候选疫苗从开发到分销快速有效推进的关键决定因素。

领先的研究、研发和製造合作伙伴如何建构产品组合、合作和製造方法以获得转换优势

HIV疫苗生态系统中的领先研究机构正在不断改进其产品组合和伙伴关係方式，以应对科学进步和不断变化的营运限制。公共研究机构持续提供基础免疫学见解，为转化项目提供资讯；而製药和生物技术开发商则将新型抗原设计与先进的递送平台相结合，以优化免疫的持久性和广度。策略合作通常将平台专家与提供临床试验基础设施和本地生产能力的组织配对，从而加快规模化进程并提高试验入组效率。

整合模组化製造能力和灵活CMC（化学、製造和控制）流程的公司往往能够更顺利地管理临床转换。投资低温运输创新、品质源自于设计製造和可扩展分析的公司正在增强其支持跨区域扩张的能力。同时，提供端到端服务和监管经验的受託製造厂商(CDMO) 对专案进度至关重要，尤其是在需要区域内製造和技术转移的情况下。在整个生态系统中，竞争优势在于那些将科学新颖性与营运执行、监管前瞻性和协作敏捷性相结合的营业单位。

专案领导者应采取切实可行的策略行动，平衡平台可选性、供应链弹性、监管参与度和公平准入伙伴关係

产业领导者应将近期战术性行动与策略蓝图结合，以平衡科学风险、营运韧性和可及性目标。早期投资组合优先考虑平台无关性，以保持重组蛋白、类病毒颗粒、核苷酸构建体和病毒载体的多样性。同时，他们投资于特定模式的下游能力，例如製剂科学、低温运输物流和给药途径优化，以减轻后期转化阻力。

透过实现关键投入品供应商多元化、探索近岸外包和区域製造伙伴关係关係以及在采购合约中纳入关税应急条款，增强供应链弹性。透过及早与监管机构接触、推行统一的终端和自适应测试框架来加强监管策略，这有助于在保持强有力的安全监督的同时加快证据生成。此类模式应包括清晰的管治、智慧财产权管理策略以及协调公共和私人相关人员之间奖励的共用上市计划。此类模式应包括清晰的管治、智慧财产权管理策略以及协调公共和私人相关人员之间奖励的共用上市计划。

我们透明且可重复的调查方法将主要专家访谈与次要科学和监管证据相结合，以提供可行的项目见解

本报告整合了主要和次要讯息，建构了严谨且可重复的HIV疫苗发展态势。主要资讯包括对临床研究人员、生产专家、监管顾问和采购相关人员的结构化访谈，以及来自积极应对开发和规模化挑战的后期专案经理的匿名定性回馈。次要资讯则参考了同行评审文献、官方监管指南、临床试验註册中心和会议报告，以分析科学趋势并检验转化假设。

我们优先考虑分析方法的透明度，记录关于技术性能、供应链约束和监管途径的假设，并透过敏感度检验来探索平台采用和生产策略的替代方案。在适用的情况下，我们的结论强调基于证据的相关性，而非推测性预测。我们的调查方法支援按技术、给药途径和地区进行自订筛选，为需要针对合作、采购和临床策略制定进行重点分析的决策者提供伙伴关係的、可提取的洞察。

整合技术、监管、供应链和区域方面的考虑，确定将爱滋病毒疫苗创新转化为可用解决方案的现实途径

总而言之，HIV疫苗领域的特点是技术多样性加速发展、监管格局不断演变，以及对供应链和区域部署现状的日益关注。保持平台灵活性、投资特定给药途径的营运能力，并积极与区域相关人员合作的开发商，将更有能力将科学进步转化为可行的产品。不断变化的关税和贸易政策凸显了弹性采购和生产策略的重要性，而市场区隔和区域动态则凸显了需要根据最终用户需求和分销通路现状制定量身定制的方案。

从前景光明的免疫原到广泛可用的疫苗，需要一个涵盖科学、生产、监管和商业性途径的综合计划。策略伙伴关係、模组化生产方法和早期监管对话将继续加速专案进展。最终，成功的专案将技术创新与切实可行的实施计划相结合，这些计划以公平获取为中心，同时预见政策和物流的限制。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 基于 mRNA 的 HIV 候选疫苗的进展展现出更广泛的免疫反应和持久的保护
  • 开发镶嵌抗原製剂以针对多种爱滋病毒株并提高覆盖率
  • 将广泛中和抗体诱导方法整合到下一代爱滋病毒疫苗研究管道中
  • 采用奈米颗粒递送系统提高抗原稳定性和标靶免疫激活
  • 在撒哈拉以南非洲高发生率地区启动预防性爱滋病毒疫苗大规模临床试验
  • 生物技术与学术合作加速爱滋病毒候选疫苗的开发与测试
  • 新的法规结构有利于加速核准具有良好安全性的有前景的爱滋病毒候选疫苗

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. HIV疫苗市场（依疫苗类型）

  • 预防
    • 灭活病毒
    • 减毒活病毒
    • 重组蛋白
    • 类病毒颗粒
  • 治疗

9. HIV疫苗市场（依技术）

  • DNA
  • mRNA
    • 常规mRNA
    • 自我扩增的mRNA
  • 胜肽
  • 病毒载体

第十章 HIV 疫苗市场（依给药途径）

  • 肌肉注射
  • 鼻内
  • 皮下

第 11 章 HIV 疫苗市场（以最终用户划分）

  • 诊所
    • 医院附设诊所
    • 独立诊所
  • 医院
    • 私立医院
    • 公立医院
  • 製药公司
  • 研究机构

第 12 章：爱滋病毒疫苗市场（按分销管道）

  • 直销
  • 网上销售
  • 零售药局

13. HIV疫苗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章：爱滋病毒疫苗市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国爱滋病疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Johnson & Johnson, Inc.
    • Moderna, Inc.
    • BioNTech SE
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Novavax, Inc.
    • CureVac NV
    • Bavarian Nordic GmbH
Product Code: MRR-4312A385A507

The HIV Vaccines Market is projected to grow by USD 2,552.37 million at a CAGR of 13.29% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 940.05 million
Estimated Year [2025] USD 1,064.16 million
Forecast Year [2032] USD 2,552.37 million
CAGR (%) 13.29%

Concise orientation to the converging scientific, regulatory, and operational forces reshaping HIV vaccine development and program priorities

HIV vaccine development occupies a pivotal role at the intersection of immunology, virology, and global public health strategy. Recent scientific advances in antigen design, delivery platforms, and immune modulation techniques have reframed what is technically achievable, while regulatory frameworks and clinical trial designs continue to adapt to novel modalities. Stakeholders across public health institutions, academic consortia, and private developers are navigating a landscape shaped by complex scientific trade-offs, evolving public expectations, and the need for sustainable manufacturing and distribution approaches.

This executive summary aims to synthesize the most consequential developments and to surface strategic implications for decision-makers. It clarifies how shifts in platform technology preferences, regulatory alignment, and geopolitical dynamics are influencing priorities across development portfolios. The summary also highlights how route of administration choices, end-user requirements, and distribution channels intersect with technology selection and clinical strategy. By framing these factors together, the introduction sets the stage for actionable insight that supports program prioritization, partnership formation, and operational planning across research, clinical, and commercial stakeholders.

How platform diversification, administration route optimization, regulatory harmonization, and collaborative models are jointly transforming HIV vaccine strategies

The HIV vaccine landscape is undergoing several transformative shifts that are redefining research strategies, investment priorities, and the architecture of collaboration. First, platform diversification is driving parallel development pathways: while traditional approaches like recombinant protein and virus-like particle constructs retain importance for certain immune profiles, nucleotide-based platforms such as conventional mRNA and self-amplifying mRNA are catalyzing renewed interest due to their rapid design cycles and flexible antigen presentation. At the same time, viral vectors and peptide strategies continue to be refined to improve safety, durability of response, and targeted cellular immunity.

Second, integration of immunogen design with delivery route selection is emerging as a critical determinant of clinical strategy. Intramuscular administration remains the default for many candidates, but intranasal and subcutaneous routes are being reexamined for mucosal immunity and dose-sparing advantages respectively. Third, regulatory agencies are increasingly emphasizing harmonized endpoints, adaptive trial designs, and real-world data integration, which accelerates translational pathways but requires robust post-authorization evidence plans. Finally, collaboration models are shifting: multi-stakeholder consortia, public-private partnerships, and novel licensing arrangements are becoming standard mechanisms to balance scientific risk, capital intensity, and global access objectives. These shifts collectively expand the set of feasible strategies for program leaders while raising the premium on integrated technical, regulatory, and commercial planning.

Assessing how 2025 tariff shifts are reshaping sourcing, manufacturing footprints, and collaborative production strategies across the HIV vaccine value chain

Tariff policy changes announced in and around 2025 have introduced a new set of considerations for vaccine supply chains, procurement strategies, and cross-border collaboration. Increased duties on certain raw materials, components, and finished products can impact the cost competitiveness of manufacturing footprints and influence decisions about where to site production for finished vaccines or key intermediates. These dynamics amplify the importance of supply chain visibility and of strategic sourcing that reduces dependence on single-country suppliers for critical reagents and consumables.

Beyond direct cost effects, tariff shifts can create operational frictions that extend lead times and complicate inventory planning. Manufacturers and distributors respond by diversifying supplier networks, increasing onshore or nearshore manufacturing capacity, and renegotiating long-term supply agreements to incorporate tariff contingencies. Procurement teams must also adjust contracting language to address customs compliance, tariff mitigation clauses, and potential regulatory variances that arise when products cross multiple jurisdictions.

Importantly, tariffs can influence collaborative structures: research collaborations and manufacturing partnerships may emphasize in-region production and technology transfer to avoid cross-border cost penalties and to align with national industrial policies. Policymakers and industry alike are assessing how tariff instruments affect equitable access objectives, with a growing emphasis on cooperative mechanisms that preserve affordability while supporting resilient manufacturing ecosystems.

Integrated segmentation insights that connect vaccine type, platform technology, administration route, end-user dynamics, and distribution choices to strategic decision-making

A nuanced view of segmentation reveals how product strategy, technology choice, administration route, user needs, and distribution pathways interact to determine development and commercialization priorities. When evaluating vaccine type, preventive approaches encompass traditional inactivated virus, live attenuated constructs, recombinant protein assets, and virus-like particle candidates, each offering distinct immunogenicity profiles and manufacturing implications; therapeutic candidates pursue different endpoints and patient cohorts, influencing clinical design and long-term engagement with healthcare systems. Technology selection spans DNA, mRNA, peptide, and viral vector platforms, where the mRNA category itself differentiates between conventional mRNA constructs and self-amplifying mRNA that aim to enhance antigen expression and dose efficiency.

Route of administration considerations-intramuscular, intranasal, and subcutaneous-affect both the immunological rationale and the operational logistics of deployment, shaping cold chain requirements and administration training. End-user segmentation highlights divergent requirements from clinics, hospitals, pharmaceutical companies, and research institutes; within clinics, the distinction between hospital-affiliated clinics and standalone clinics informs procurement channels and patient flow design, while private and public hospitals exhibit different purchasing frameworks and budgetary cycles. Distribution channel choices, including direct sales, online sales, and retail pharmacies, further determine engagement models with healthcare providers and patient access pathways. Together, these segmentation dimensions create a multidimensional decision matrix for developers and program managers that must be reconciled across scientific, regulatory, and commercial timelines.

Regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory alignment and deployment readiness

Regional dynamics are central to strategic planning for HIV vaccine development, regulatory strategy, and deployment. In the Americas, regulatory jurisdictions exhibit a mix of advanced clinical trial infrastructure and diverse payer landscapes, which encourages staged clinical pathways and partnerships with both academic centers and commercial manufacturers. Intellectual property frameworks and procurement mechanisms vary across countries, so cross-border strategies often prioritize early engagement with national regulators and payers to align evidence packages with reimbursement expectations.

Europe, Middle East & Africa presents a complex mosaic where regulatory harmonization initiatives coexist with significant variability in manufacturing capacity and healthcare access. This region emphasizes the need for flexible development plans that accommodate diverse clinical trial populations and that integrate technology transfer elements to build sustainable local capacity. Engagement with regional public health bodies and multilateral procurement entities is often essential to ensure broad access and to coordinate rollout priorities.

Asia-Pacific demonstrates a range of capabilities from high-volume manufacturing hubs to rapidly modernizing regulatory systems and extensive clinical trial networks. Developers frequently pursue regional manufacturing arrangements and strategic licensing to leverage production scale and to navigate national regulatory requirements. Across all regions, local stakeholder relationships, regulatory clarity, and manufacturing resilience remain key determinants of how quickly and effectively vaccine candidates progress from development to delivery.

How leading research institutes, developers, and manufacturing partners are structuring portfolios, collaborations, and manufacturing approaches to gain translational advantage

Leading organizations across the HIV vaccine ecosystem are evolving their portfolios and partnership approaches in response to scientific progress and shifting operational constraints. Public research institutions continue to supply fundamental immunology insights that feed translational programs, while pharmaceutical and biotech developers are combining novel antigen designs with advanced delivery platforms to optimize immune durability and breadth. Strategic collaborations frequently pair platform specialists with organizations that provide clinical trial infrastructure or regional manufacturing capacity, enabling faster scale-up and more efficient study enrollment.

Companies that integrate modular manufacturing capabilities and flexible CMC (chemistry, manufacturing, and controls) processes tend to manage clinical transitions more smoothly. Firms investing in cold chain innovation, quality-by-design manufacturing, and scalable analytics strengthen their ability to support multi-regional rollouts. Meanwhile, contract development and manufacturing organizations (CDMOs) that offer end-to-end services and regulatory experience are increasingly central to program timelines, especially where in-region production or technology transfer is required. Across the ecosystem, competitive advantage accrues to entities that align scientific novelty with operational execution, regulatory foresight, and collaborative agility.

Practical strategic actions for program leaders to balance platform optionality, supply chain resilience, regulatory engagement, and equitable access partnerships

Industry leaders should align near-term tactical actions with a strategic roadmap that balances scientific risk, operational resilience, and access objectives. Prioritize platform agnosticism in early-stage portfolios to preserve optionality between recombinant protein, virus-like particles, nucleotide-based constructs, and viral vectors; this approach allows programs to pivot as clinical data clarifies correlates of protection and durability signals. Simultaneously, invest in modality-specific downstream capabilities such as formulation science, cold chain logistics, and route-of-administration optimization to reduce late-stage translational friction.

Strengthen supply chain resilience by diversifying suppliers for critical inputs, exploring nearshoring or regional manufacturing partnerships, and embedding tariff contingency clauses in procurement contracts. Enhance regulatory strategy by engaging regulators early and pursuing harmonized endpoints and adaptive trial frameworks that support accelerated evidence generation while maintaining robust safety oversight. Finally, develop partnership models that enable technology transfer, local capacity building, and equitable access arrangements; such models should include clear governance, IP management strategies, and shared go-to-market plans that align incentives across public and private stakeholders. These actions collectively reduce program risk and increase the likelihood that promising candidates can progress efficiently from clinical proof-of-concept to broad availability.

Transparent, reproducible research methodology combining primary expert interviews and secondary scientific and regulatory evidence to inform actionable program insights

This report synthesizes primary and secondary inputs to construct a rigorous, reproducible view of the HIV vaccine landscape. Primary inputs include structured interviews with clinical investigators, manufacturing experts, regulatory advisors, and procurement stakeholders, combined with anonymized qualitative feedback from late-stage program managers who are actively navigating development and scale-up challenges. Secondary inputs draw on peer-reviewed literature, public regulatory guidance, clinical trial registries, and conference disclosures to triangulate scientific trends and to validate translational assumptions.

Analysis prioritizes methodological transparency: assumptions about technology performance, supply chain constraints, and regulatory pathways are documented, and sensitivity checks explore alternative scenarios for platform adoption and manufacturing strategies. Where applicable, conclusions emphasize evidence-based linkages rather than speculative projections. The methodology supports custom filtering by technology, route of administration, and region, enabling tailored extractable insights for decision-makers who require focused analysis for partnerships, procurement, or clinical strategy development.

Synthesis of technology, regulatory, supply chain, and regional considerations that define the practical pathways to translating HIV vaccine innovation into accessible solutions

In conclusion, the HIV vaccine landscape is characterized by accelerating technological diversity, evolving regulatory expectations, and heightened attention to supply chain and regional deployment realities. Developers who maintain platform flexibility, invest in operational capabilities that align with chosen administration routes, and proactively engage with regional stakeholders will be better positioned to translate scientific advances into deliverable products. Tariff and trade policy shifts underscore the importance of resilient sourcing and manufacturing strategies, while segmentation and regional dynamics highlight the need for tailored approaches that reflect end-user requirements and distribution channel realities.

The path from promising immunogen to widely accessible vaccine requires integrated planning across science, manufacturing, regulation, and commercial pathways. Strategic partnerships, modular manufacturing approaches, and early regulatory dialogue will continue to accelerate program progression. Ultimately, successful programs will be those that pair technical innovation with pragmatic execution plans that anticipate policy and logistical constraints while centering equitable access objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advancements in mRNA-based HIV vaccine candidates demonstrating broader immune responses and durable protection
  • 5.2. Development of mosaic antigen formulations aiming to target multiple HIV strains with enhanced coverage
  • 5.3. Integration of broadly neutralizing antibody inducement approaches into next generation HIV vaccine research pipelines
  • 5.4. Adoption of nanoparticle delivery systems to improve antigen stability and targeted immune activation in HIV vaccines
  • 5.5. Initiation of large scale clinical trials focusing on preventative HIV vaccines in high incidence regions of sub-Saharan Africa
  • 5.6. Collaboration between biotechnology firms and academic institutions to accelerate HIV vaccine candidate development and testing
  • 5.7. Emerging regulatory frameworks facilitating accelerated approval pathways for promising HIV vaccine candidates with strong safety profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Vaccines Market, by Vaccine Type

  • 8.1. Preventive
    • 8.1.1. Inactivated Virus
    • 8.1.2. Live Attenuated Virus
    • 8.1.3. Recombinant Protein
    • 8.1.4. Virus-Like Particle
  • 8.2. Therapeutic

9. HIV Vaccines Market, by Technology

  • 9.1. Dna
  • 9.2. Mrna
    • 9.2.1. Conventional Mrna
    • 9.2.2. Self-Amplifying Mrna
  • 9.3. Peptide
  • 9.4. Viral Vector

10. HIV Vaccines Market, by Route Of Administration

  • 10.1. Intramuscular
  • 10.2. Intranasal
  • 10.3. Subcutaneous

11. HIV Vaccines Market, by End User

  • 11.1. Clinics
    • 11.1.1. Hospital-Affiliated Clinics
    • 11.1.2. Standalone Clinics
  • 11.2. Hospitals
    • 11.2.1. Private Hospitals
    • 11.2.2. Public Hospitals
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Institutes

12. HIV Vaccines Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Online Sales
  • 12.3. Retail Pharmacies

13. HIV Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. HIV Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. HIV Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Johnson & Johnson, Inc.
    • 16.3.2. Moderna, Inc.
    • 16.3.3. BioNTech SE
    • 16.3.4. GlaxoSmithKline plc
    • 16.3.5. Sanofi S.A.
    • 16.3.6. Merck & Co., Inc.
    • 16.3.7. Pfizer Inc.
    • 16.3.8. Novavax, Inc.
    • 16.3.9. CureVac N.V.
    • 16.3.10. Bavarian Nordic GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HIV VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HIV VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HIV VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HIV VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HIV VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HIV VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HIV VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HIV VACCINES MARKET SIZE, BY INACTIVATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HIV VACCINES MARKET SIZE, BY LIVE ATTENUATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HIV VACCINES MARKET SIZE, BY RECOMBINANT PROTEIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HIV VACCINES MARKET SIZE, BY VIRUS-LIKE PARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HIV VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HIV VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HIV VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HIV VACCINES MARKET SIZE, BY CONVENTIONAL MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HIV VACCINES MARKET SIZE, BY SELF-AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HIV VACCINES MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HIV VACCINES MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HIV VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HIV VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HIV VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HIV VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITAL-AFFILIATED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HIV VACCINES MARKET SIZE, BY STANDALONE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HIV VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HIV VACCINES MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HIV VACCINES MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HIV VACCINES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HIV VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HIV VACCINES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HIV VACCINES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HIV VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HIV VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS HIV VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 297. MIDDLE EAST HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 298. MIDDLE EAST HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 316. AFRICA HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 317. AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 318. AFRICA HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 319. AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. AFRICA HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 334. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 335. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 336. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 337. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 338. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 339. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 340. ASIA-PACIFIC HIV VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 341. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 342. GLOBAL HIV VACCINES MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 343. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 344. ASEAN HIV VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 345. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 346. ASEAN HIV VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 347. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2024 (USD MILLION)
  • TABLE 348. ASEAN HIV VACCINES MARKET SIZE, BY PREVENTIVE, 2025-2032 (USD MILLION)
  • TABLE 349. ASEAN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 350. ASEAN HIV VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 351. ASEAN HIV VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 352. ASEAN HIV VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 353. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 354. ASEAN HIV VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 355. ASEAN HIV VACC